OnKure
Manufacturing · Colorado, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
6707 Winchester Cir Ste 400, Boulder, Co...Phone Number
(720) 307-2892Website
www.onkuretherapeutics.comRevenue
-Stock Symbol
OKURIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
2
1
1
1
1
About OnKure
Onkure Therapeutics is a clinicalstage biopharmaceutical company focused on discovering and developing innovative therapies for patients with cancer and serious diseases. Its research platform centers on identifying novel targets and advancing tailored treatments designed to address underlying biological mechanisms with high unmet medical need. Independent observers view Onkure as part of the evolving oncology and precision medicine landscape, bridging scientific discovery and clinical development in pursuit of therapies that may offer meaningful benefit where existing options are limited, while maintaining rigorous scientific evaluation and safety standards.Explore more
OnKure Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is OnKure your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on OnKure recently announced quarterly report
Funding: Get notified immidiatlly once OnKure has new funding data
Click to see if OnKure had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at OnKure
Check if OnKure has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when OnKure launches new products
Check out if OnKure is spiking on competitors!
OnKure, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Recommended Actions
Reach out to Masked Content who joined OnKure as Masked Content
Find 3 more new buyers
Compare Similar Companies to OnKure
Compare insights from companies similar to OnKure, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
OnKure is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
OnKure is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about OnKure.
OnKure financials insights
Gather financial insights about OnKure, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2018
Series A
$7M
2021
Series B
$55M
2023
Series C
$54M
2026
Stock/Share Issuance
$150M
OnKure Tech Stack
A closer look at the technologies used by OnKure
See more technologies
Most Recent Scoops
Funding
Funding
Project
plans next development steps for OKI-219, including a combination study with fulvestrant in ER+/HER2- breast cancer patients, potential triplet studies with CDK4/6 inhibitors, and exploring utility in HER2+ breast cancer. An update on the fulvestrant combination study is expected in the second half of this year.
Research & Development, Medical Research, Pharmaceuticals, Clinical Operations
Project
OnKure is developing inhibitors for PI3K alpha, the most frequently mutated protein across cancers, particularly in solid tumors such as breast, lung, head and neck, and prostate cancers.
Research & Development, Medical Research, Pharmaceuticals
Project
OnKure is pursuing allosteric inhibitors for PI3K alpha to achieve high selectivity for mutant forms while sparing wild-type, aiming to avoid on-target toxicities like hyperglycemia and metabolic perturbations.
Research & Development, Medical Research, Pharmaceuticals
Project
Research & Development, Medical Research, Pharmaceuticals
OnKure News & Media
Access Industries (OKUR) discloses 19.99% OnKure stake and board right - Stock Titan
Access-linked entities report 9.09M OnKure shares, a 19.99% stake, via stock and pre-funded warrants, plus a board seat and resale registration rights from a March 2026 private placement.OnKure CMO granted 110,000 stock options | OKUR Insider Trading
OnKure CMO Samuel Agresta receives 110,000 stock options at a $4.07 exercise price, vesting monthly from May 1, 2026, and expiring March 31, 2036.OnKure Therapeutics Raises $150 Million in Private Placement; Enters Registration Rights Pact
OnKure Therapeutics announced a private placement expected to raise approximately $150.0 million through the sale of common stock and pre-funded warrants to institutional investors, with closing anticipated on Mar 31, 2026. Shares will be priced at $4.15 and pre-funded warrants at $4.1499 per under…OnKure Therapeutics Announces Oversubscribed $150 Million Private Placement to Advance Next-Generation PI3Kα Pan-Mutant Selective Inhibitor Candidates in Breast Cancer and Vascular Anomalies
-- Financing led by Access Biotechnology with participation from new and existing investors
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding OnKure
Sign Up For FreeTo access detailed company insights
Onkure Therapeutics is a clinicalstage biopharmaceutical company focused on discovering and developing innovative therapies for patients with cancer and serious diseases. Its research platform centers on identifying novel targets and advancing tailored treatments designed to address underlying biological mechanisms with high unmet medical need. Ind... Read More
